Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity chemotherapy with or without imatinib in older unfit patients with untreated AML or high-risk RAEB/RAEB-T
NL-OMON25417Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib, cytarabine and daunorubicin in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoint: Complete remission rate. Started Jan 2006; status: active, not recruiting.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON25417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25417.